Speaker: Erika Penz, MD, MSc, FRCPC, University of Saskatchewan, Saskatoon, SK
Moderator: MyLinh Duong MBBS, MSc, FRACP, McMaster University, Hamilton, ON
Our goal as physicians has always been to prevent and treat illness as well as alleviate suffering for our patients. The opportunity to reduce mortality for our patients living with COPD has historically been limited. With the most recent ETHOS and IMPACT clinical trials, and together with the historical context of prior studies aimed at reducing mortality, there is now evidence and renewed hope for treatments that can achieve a mortality benefit. In addition, there is a pressing need to recognize the significant role of cardiovascular disease (CVD) on the health outcomes of our COPD patients. We will discuss what we know, where current gaps exist in our understanding of COPD and CVD, and how we can change the care pathway for our patients.
Learning Objectives
At the end of this presentation, attendees will be able to:
- Describe the impact of moderate and severe exacerbations on mortality and CV outcomes;
- Discuss emerging data to support the use of triple therapies on reducing patient mortality; and
- Assess CV risk factors and comorbidities to identify COPD patients at risk of increased mortality.
CanMEDS Roles: Collaborator, Communicator, Medical Expert
This session is co-developed by the CTS and AstraZeneca and is planned to achieve scientific integrity, objectivity and balance.
